Application of saponin in preparation of anti-mycoplasma bovis product

A technology of Mycoplasma bovis and saponins, applied in the application field of saponin compounds in the preparation of anti-Mycoplasma bovis products

Active Publication Date: 2021-11-19
INST OF ANIMAL SCI & VETERINARY MEDICINE SHANDONG ACADEMY OF AGRI SCI
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far there is no report about its use in th

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of saponin in preparation of anti-mycoplasma bovis product
  • Application of saponin in preparation of anti-mycoplasma bovis product
  • Application of saponin in preparation of anti-mycoplasma bovis product

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0067] Embodiment 1 tea saponin suppresses the effect verification of bovis mycoplasma

[0068] 1. Toxicity test of tea saponin on MDBK cells:

[0069] MDBK cells are susceptible cells to M. bovis. Therefore, first detect the cytotoxicity of tea saponin to MDBK cells, the specific experimental steps are as follows:

[0070] (1) Inoculate 100 μL cells (MDBK 5000 cells / well) in a 96-well plate.

[0071] (2) After culturing for about 12 hours, the next step of drug addition analysis was carried out. Discard the medium, add 100 μL of 2% FBS DMEM containing different drug concentrations to each well, and make 3 parallels for each concentration. At the same time, control wells: add 100 μL of 2% FBS DMEM medium containing 0.9% DMSO. Zero well: no cells are plated.

[0072] (3) At 37°C, 5% CO 2 After culturing for 48 h under the condition, the medium in the well was discarded. Wash twice with 100 μL PBS to exclude the influence of drugs on CCK8 response. Add 100 μL DMEM medium...

Embodiment 2 7

[0081]Embodiment 2 Sodium aescinate inhibits Mycoplasma bovis effect verification

[0082] 1. Toxicity test of sodium aescinate on MDBK cells:

[0083] Firstly, the cytotoxicity of sodium aescinate to MDBK cells was detected, and the specific experimental steps were as follows:

[0084] (1) Inoculate 100 μL cells (MDBK 5000 cells / well) in a 96-well plate.

[0085] (2) After culturing for about 12 hours, the next step of drug addition analysis was carried out. Discard the medium, add 100 μL of 2% FBS DMEM containing different drug concentrations to each well, and make 3 parallels for each concentration. At the same time, control wells: add 100 μL of 2% FBS DMEM medium containing 0.9% DMSO. Zero well: no cells are plated.

[0086] (3) At 37°C, 5% CO 2 After culturing for 48 h under the condition, the medium in the well was discarded. Wash twice with 100 μL PBS to exclude the influence of drugs on CCK8 response. Add 100 μL DMEM medium + 10 μL CCK8 solution to each well.

...

Embodiment 3

[0095] Embodiment 3 Diosgenin inhibits Mycoplasma bovis effect verification

[0096] 1. Toxicity test of diosgenin on MDBK cells:

[0097] Firstly, the cytotoxicity of diosgenin to MDBK cells was detected, and the specific experimental steps were as follows:

[0098] (1) Inoculate 100 μL cells (MDBK 5000 cells / well) in a 96-well plate.

[0099] (2) After culturing for about 12 hours, the next step of drug addition analysis was carried out. Discard the medium, add 100 μL of 2% FBS DMEM containing different drug concentrations to each well, and make 3 parallels for each concentration. At the same time, control wells: add 100 μL of 2% FBS DMEM medium containing 0.9% DMSO. Zero well: no cells are plated.

[0100] (3) At 37°C, 5% CO 2 After culturing for 48 h under the condition, the medium in the well was discarded. Wash twice with 100 μL PBS to exclude the influence of drugs on CCK8 response. Add 100 μL DMEM medium + 10 μL CCK8 solution to each well.

[0101] (4) 37°C, 5%...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of saponin in preparation of an anti-mycoplasma bovis product. Mycoplasma bovis can cause various diseases such as bovine pneumonia, arthritis, bovine mastitis and the like, medicines for preventing and treating the bovine mycoplasma diseases in the field are very limited, the advanced treatment effect is not ideal, and prevention and control are mainly carried out in a mode of enhancing feeding management. The invention provides the activity of tea saponin, dioscin and sodium aescinate for inhibiting mycoplasma bovis in vitro, the related research of saponin compounds on mycoplasma inhibition in the prior art is relatively blank, and the compounds not only have a good inhibition effect on mycoplasma bovis, but also have relatively small toxicity on normal cells, so that the compound has a prospect of being developed into an anti-mycoplasma bovis drug.

Description

technical field [0001] The invention belongs to the technical field of anti-mycoplasma bovis drugs, and in particular relates to the application of saponin compounds in the preparation of anti-mycoplasma bovis products. Background technique [0002] The information disclosed in this background section is only intended to increase the understanding of the general background of the present invention, and is not necessarily taken as an acknowledgment or any form of suggestion that the information constitutes the prior art already known to those skilled in the art. [0003] Mycoplasma bovis (Mycoplasma bovis) is one of the important pathogens that cause various symptoms such as pneumonia and arthritis in calves and mastitis in adult cattle. Since Hale et al first isolated Mycoplasma bovis from milk in the United States in 1961, Mycoplasma bovis has been isolated from all over the world. In 2008, Mycoplasma bovis pneumonia broke out in beef cattle for the first time in my countr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/704A61K31/7048A61K49/00A61K39/02A61K51/00A61P31/04A23K10/00A23K50/10A23K50/00
CPCA61K31/704A61K31/7048A61K49/00A61K39/0241A61K51/00A61P31/04A23K10/00A23K50/10A23K50/00
Inventor 张亮朱曼玲张云飞杨宏军陈九杨美
Owner INST OF ANIMAL SCI & VETERINARY MEDICINE SHANDONG ACADEMY OF AGRI SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap